Furthermore, a recent study demonstrated that targeting the proangiogenic pathway using the anticancer drug axitinib, a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-KIT receptors, dramatically reduced cerebrovascular angiogenesis and promoted blood-brain barrier integrity, resulting in improved Aβ clearance and diminished brain Aβ burden in a mouse model of AD [13]. This evidence concerns the gene KDR and Alzheimer disease.